ID
38189
Descrição
Study ID: 111539 Clinical Study ID: 111539 Study Title: A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of scalating Repeat Doses of GSK249320 in Patients With Stroke Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00833989 https://clinicaltrials.gov/ct2/show/NCT00833989 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Refanezumab, Placebo Trade Name: N/A Study Indication: Ischaemic Attack, Transient The study consists of 8 visits: Day 1, Week 1 (Day 5), Week 2 (Day 10), Week 4 (Day 30), Week 8 (Day 60), Week 12 (Day 90), Week 16 (Day 112), Follow-up (F/U). All subjects will receive two doses. The first dose within 24-72 hrs after stroke the second dose 9 +/- 1 days after the first one. Each dose will be given as an intravenous infusion over 60 minutes. This document contains the demography form. It has to be filled in for Day 1.
Link
https://clinicaltrials.gov/ct2/show/NCT00833989
Palavras-chave
Versões (1)
- 25/09/2019 25/09/2019 -
Titular dos direitos
GlaxoSmithKline
Transferido a
25 de setembro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Safety, Pharmacokinetics and Pharmacodynamics of Refanezumab in Patients with Stroke, NCT00833989
Similar models
Demography
- StudyEvent: ODM
C2986440 (UMLS CUI [1,2])
C0085756 (UMLS CUI [2])
C0027567 (UMLS CUI [3])
C1515945 (UMLS CUI [2])
C0238696 (UMLS CUI [2])
C1519427 (UMLS CUI [3])
C4540996 (UMLS CUI [2])
C1556094 (UMLS CUI [2])
C0238697 (UMLS CUI [2])
C1513907 (UMLS CUI [2])
C0238604 (UMLS CUI [2])
C2698217 (UMLS CUI [3])
C0043157 (UMLS CUI [2])